IDH2 and glioblastoma: A group of IDH-mutant GBM cases (n = 75) with methylation information from MGMT promoter CpG sites 75–78 was selected and compared with IDH-wildtype GBM cases (n = 173) for MGMT promoter methylation, age, and gender distribution.